Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)

CompletadoFase 3ClinicalTrials.gov

ID: NCT00358436Tipo: INTERVENTIONALInicio: 1 de ago de 2006Fin estimado: 1 de jun de 2008

Traducción no disponible, mostrando original

Resumen

To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.

Elegibilidad

Edad mínima: 40 YearsSexo: ALL

Criterios de inclusión

Males and females aged ≥ 40 years with a clinical diagnosis of moderate to severe stable COPD

Criterios de exclusión

History or current diagnosis of asthma, recent respiratory tract infection or acute COPD exacerbation, life expectancy of less than 1 year, known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma

Intervenciones

drug

Aclidinium bromide

Aclidinium bromide 200 μg once-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks

drug

Placebo

Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks

Ubicaciones

Almirall Investigational Sites#800

Buenos Aires, Argentina

Almirall Investigational Sites#744

Buenos Aires, Argentina

Almirall Investigational Sites#792

Buenos Aires, Argentina

Almirall Investigational Sites#793

Buenos Aires, Argentina

Almirall Investigational Sites#799

Buenos Aires, Argentina

Almirall Investigational Sites#795

Buenos Aires, Argentina

Almirall Investigational Sites#801

Buenos Aires, Argentina

Almirall Investigational Sites#791

Buenos Aires, Argentina

Almirall Investigational Sites#797

El Palomar, Argentina

Almirall Investigational Sites#740

La Plata, Argentina

Almirall Investigational Sites#801

Rosario, Argentina

Almirall Investigational Sites#796

San Miguel de Tucumán, Argentina

Almirall Investigational Sites#794

Vicente López, Argentina

Patrocinadores

PrincipalAstraZeneca

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

Efficacy and Safety of LAS 34273 in Patients With Moderat... | EligiMed